CD37 expression in follicular lymphoma.
CD37
FLIPI
Follicular lymphoma
Poor prognosis
Journal
Annals of hematology
ISSN: 1432-0584
Titre abrégé: Ann Hematol
Pays: Germany
ID NLM: 9107334
Informations de publication
Date de publication:
May 2022
May 2022
Historique:
received:
23
07
2021
accepted:
01
02
2022
pubmed:
17
2
2022
medline:
13
4
2022
entrez:
16
2
2022
Statut:
ppublish
Résumé
CD37 is a tetraspanin protein expressed in various B-cell lymphomas that mediates tumor survival signaling. Follicular lymphoma (FL) is a representative B-cell neoplasm composed of germinal center B cells. In recent years, CD37 has been focused on as a therapeutic target for B-cell lymphoma. The purpose of this study was to characterize CD37 expression in FL patients to identify risk factors associated with various prognostic factors. We retrospectively reviewed 167 cases of FL and evaluated the immunohistochemical expression of CD37 and its statistical association with clinicopathological features. Immunohistochemically, CD37 was observed in the cytoplasm and/or membrane of neoplastic cells, mainly in neoplastic follicles to various extents. One hundred cases (100/167, 60.0%) were categorized as CD37-positive, and 67 cases were CD37-negative. In cases with high Follicular Lymphoma International Prognostic Index (FLIPI), CD37-negative cases had a poor overall survival compared with CD37-positive cases (P = 0.047), although no significant differences were observed in other clinicopathologic factors, including histological grade, BCL2-IGH translocation, and immunohistochemical phenotype. Therefore, CD37 protein may play a role in tumor progression and may serve as a therapeutic target. However, further studies are needed to explore its significance.
Identifiants
pubmed: 35171311
doi: 10.1007/s00277-022-04785-z
pii: 10.1007/s00277-022-04785-z
doi:
Substances chimiques
Antigens, Neoplasm
0
CD37 protein, human
0
Tetraspanins
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1067-1075Informations de copyright
© 2022. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.
Références
Swerdlow SH, Campo E, Pileri SA, Harris NL, Stein H, Siebert R et al (2016) The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood 127(20):2375–2390
doi: 10.1182/blood-2016-01-643569
Muto R, Miyoshi H, Sato K, Furuta T, Muta H, Kawamoto K et al (2018) Epidemiology and secular trends of malignant lymphoma in Japan: analysis of 9426 cases according to the World Health Organization classification. Cancer Med 7(11):5843–5858
doi: 10.1002/cam4.1805
Solal-Céligny P, Roy P, Colombat P, White J, Armitage JO, Arranz-Saez R et al (2004) Follicular Lymphoma International Prognostic Index. Blood 104(5):1258–1265
doi: 10.1182/blood-2003-12-4434
Federico M, Bellei M, Marcheselli L, Luminari S, Lopez-Guillermo A, Vitolo U et al (2009) Follicular Lymphoma International Prognostic Index 2: a new prognostic index for follicular lymphoma developed by the international follicular lymphoma prognostic factor project. J Clin Oncol 27(27):4555–4562
doi: 10.1200/JCO.2008.21.3991
Casulo C, Byrtek M, Dawson KL, Zhou X, Farber CM, Flowers CR et al (2015) Early relapse of follicular lymphoma after rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone defines patients at high risk for death: an analysis from the National LymphoCare Study. J Clin Oncol 33(23):2516–2522
doi: 10.1200/JCO.2014.59.7534
Pastore A, Jurinovic V, Kridel R, Hoster E, Staiger AM, Szczepanowski M et al (2015) Integration of gene mutations in risk prognostication for patients receiving first-line immunochemotherapy for follicular lymphoma: a retrospective analysis of a prospective clinical trial and validation in a population-based registry. Lancet Oncol 16(9):1111–1122
doi: 10.1016/S1470-2045(15)00169-2
Lapalombella R, Yeh YY, Wang L, Ramanunni A, Rafiq S, Jha S et al (2012) Tetraspanin CD37 directly mediates transduction of survival and apoptotic signals. Cancer Cell 21(5):694–708
doi: 10.1016/j.ccr.2012.03.040
Barrena S, Almeida J, Yunta M, López A, Fernández-Mosteirín N, Giralt M et al (2005) Aberrant expression of tetraspanin molecules in B-cell chronic lymphoproliferative disorders and its correlation with normal B-cell maturation. Leukemia 19(8):1376–1383
doi: 10.1038/sj.leu.2403822
Wright MD, Moseley GW, van Spriel AB (2004) Tetraspanin microdomains in immune cell signalling and malignant disease. Tissue Antigens 64(5):533–542
doi: 10.1111/j.1399-0039.2004.00321.x
Schwartz-Albiez R, Dörken B, Hofmann W, Moldenhauer G (1988) The B cell-associated CD37 antigen (gp40–52). Structure and subcellular expression of an extensively glycosylated glycoprotein. J Immunol 140(3): 905–914
Zhao X, Lapalombella R, Joshi T, Cheney C, Gowda A, Hayden-Ledbetter MS et al (2007) Targeting CD37-positive lymphoid malignancies with a novel engineered small modular immunopharmaceutical. Blood 110(7):2569–2577
doi: 10.1182/blood-2006-12-062927
Byrd JC, Pagel JM, Awan FT, Forero A, Flinn IW, Deauna-Limayo DP et al (2014) A phase 1 study evaluating the safety and tolerability of otlertuzumab, an anti-CD37 mono-specific ADAPTIR therapeutic protein in chronic lymphocytic leukemia. Blood 123(9):1302–1308
doi: 10.1182/blood-2013-07-512137
Xu-Monette ZY, Li L, Byrd JC, abbar KJ, Manyam GC, Maria de Winde C, et al (2016) Assessment of CD37 B-cell antigen and cell of origin significantly improves risk prediction in diffuse large B-cell lymphoma. Blood 128(26):3083–3100
doi: 10.1182/blood-2016-05-715094
Shimono J, Miyoshi H, Yoshida N, Kato T, Sato K, Sugio T et al (2018) Analysis of GNA13 protein in follicular lymphoma and its association with poor prognosis. Am J Surg Pathol 42(11):1466–1471
doi: 10.1097/PAS.0000000000000969
Miyoshi H, Sato K, Yoshida M, Kimura Y, Kiyasu J, Ichikawa A et al (2014) CD5-positive follicular lymphoma characterized by CD25, MUM1, low frequency of t(14;18) and poor prognosis. Pathol Int 64(3):95–103
doi: 10.1111/pin.12145
Kanda Y (2013) Investigation of the freely available easy-to-use software ‘EZR’ for medical statistics. Bone Marrow Transplant 48(3):452–458
doi: 10.1038/bmt.2012.244
Scarfò I, Ormhøj M, Frigault MJ, Castano AP, Lorrey S, Bouffard AA et al (2018) Anti-CD37 chimeric antigen receptor T cells are active against B- and T-cell lymphomas. Blood 132(14):1495–1506
doi: 10.1182/blood-2018-04-842708
Elfrink S, de Winde CM, van den Brand M, Berendsen M, Roemer MGM, Arnold F et al (2019) High frequency of inactivating tetraspanin CD37 mutations in diffuse large B-cell lymphoma at immune-privileged sites. Blood 134(12):946–950
doi: 10.1182/blood.2019001185
Stathis A, Flinn IW, Madan S, Maddocks K, Freedman A, Weitman S et al (2018) Safety, tolerability, and preliminary activity of IMGN529, a CD37-targeted antibody-drug conjugate, in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: a dose-escalation. Phase I Study Invest New Drugs 36(5):869–876
doi: 10.1007/s10637-018-0570-4
Montoto S, Davies AJ, Matthews J, Calaminici M, Norton AJ, Amess J et al (2007) Risk and clinical implications of transformation of follicular lymphoma to diffuse large B-cell lymphoma. J Clin Oncol 25(17):2426–2433
doi: 10.1200/JCO.2006.09.3260
Hans CP, Weisenburger DD, Greiner TC, Gascoyne RD, Delabie J, Ott G et al (2004) Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood 103(1):275–282
doi: 10.1182/blood-2003-05-1545
de Winde CM, Veenbergen S, Young KH, Xu-Monette ZY, Wang XX, Xia Y et al (2016) Tetraspanin CD37 protects against the development of B cell lymphoma. J Clin Invest 126(2):653–666
doi: 10.1172/JCI81041
heng KC, van Spriel AB, Gartlan KH, Sofi M, (2009) Tetraspanins CD37 and CD151 differentially regulate Ag presentation and T-cell co-stimulation by DC. Eur J Immunol 39(1):50–55
doi: 10.1002/eji.200838798
Gartlan KH, Wee JL, Demaria MC, Nastovska R, Chang TM, Jones EL et al (2013) Tetraspanin CD37 contributes to the initiation of cellular immunity by promoting dendritic cell migration. Eur J Immunol 43(5):1208–1219
doi: 10.1002/eji.201242730
Deckert J, Park PU, Chicklas S, Yi Y, Li M, Lai KC et al (2013) A novel anti-CD37 antibody-drug conjugate with multiple anti-tumor mechanisms for the treatment of B-cell malignancies. Blood 122(20):3500–3510
doi: 10.1182/blood-2013-05-505685
Conconi A, Lobetti-Bodoni C, Montoto S, Lopez-Guillermo A, Coutinho R, Matthews J et al (2015) Life expectancy of young adults with follicular lymphoma. Ann Oncol 26(11):2317–2322
doi: 10.1093/annonc/mdv376